

Malliga R Iyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2450140/publications.pdf>

Version: 2024-02-01

38
papers

1,012
citations

430442

18
h-index

454577

30
g-index

38
all docs

38
docs citations

38
times ranked

1173
citing authors

#	ARTICLE	IF	CITATIONS
1	The therapeutic potential of second and third generation CB1R antagonists. , 2020, 208, 107477.		84
2	Antagonism of Sigma-1 Receptors Blocks Compulsive-Like Eating. Neuropsychopharmacology, 2012, 37, 2593-2604.	2.8	72
3	The μ -Receptor Antagonist BD-1063 Decreases Ethanol Intake and Reinforcement in Animal Models of Excessive Drinking. Neuropsychopharmacology, 2009, 34, 1482-1493.	2.8	69
4	Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. JCI Insight, 2016, 1, .	2.3	59
5	Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. JCI Insight, 2017, 2, .	2.3	59
6	Activation of μ -Receptors Induces Binge-like Drinking in Sardinian Alcohol-Preferring Rats. Neuropsychopharmacology, 2011, 36, 1207-1218.	2.8	53
7	Allenyl Azide Cycloaddition Chemistry. Synthesis of Pyrrolidine-Containing Bicycles and Tricycles via the Possible Intermediacy of Azatrimethylenemethane Species. Journal of the American Chemical Society, 2005, 127, 4590-4591.	6.6	44
8	Dual inhibition of cannabinoid CB ₁ receptor and inducible NOS attenuates obesity-induced chronic kidney disease. British Journal of Pharmacology, 2020, 177, 110-127.	2.7	44
9	Allenyl Azide Cycloaddition Chemistry. Synthesis of Annelated Indoles from 2-(Allenyl)phenyl Azide Substrates. Organic Letters, 2006, 8, 3113-3116.	2.4	43
10	Targeting Peripheral CB1 Receptors Reduces Ethanol Intake via a Gut-Brain Axis. Cell Metabolism, 2019, 29, 1320-1333.e8.	7.2	42
11	Allenyl Azide Cycloaddition Chemistry. 2,3-Cyclopentennelated Indole Synthesis through Indolidene Intermediates. Journal of Organic Chemistry, 2009, 74, 4958-4974.	1.7	41
12	Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines. Analytical and Bioanalytical Chemistry, 2014, 406, 5927-5937.	1.9	39
13	Cyclization Cascade of Allenyl Azides: A Dual Mechanism. Journal of the American Chemical Society, 2007, 129, 7638-7646.	6.6	35
14	Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11597-11602.	3.3	33
15	Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB ₁ R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis. Journal of Medicinal Chemistry, 2017, 60, 1126-1141.	2.9	31
16	Sigma-1 receptor mediates acquisition of alcohol drinking and seeking behavior in alcohol-preferring rats. Behavioural Brain Research, 2015, 287, 315-322.	1.2	29
17	Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB ₁ R) Antagonist. ACS Pharmacology and Translational Science, 2021, 4, 1175-1187.	2.5	29
18	Allenyl Azide Cycloaddition Chemistry: Exploration of the Scope and Mechanism of Cyclopentennelated Dihydropyrrole Synthesis through Azatrimethylenemethane Intermediates. Journal of Organic Chemistry, 2008, 73, 5090-5099.	1.7	25

#	ARTICLE	IF	CITATIONS
19	Synthesis and immunological effects of heroin vaccines. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 7211-7232.	1.5	25
20	CB ₁ R and iNOS are distinct players promoting pulmonary fibrosis in Hermansky-Pudlak syndrome. <i>Clinical and Translational Medicine</i> , 2021, 11, e471.	1.7	16
21	Therapeutic approaches targeting the neurotensin receptors. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 361-386.	2.4	15
22	Dual inhibition of CB ₁ receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID-19. <i>British Journal of Pharmacology</i> , 2022, 179, 2121-2127.	2.7	15
23	Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade. <i>Expert Opinion on Therapeutic Patents</i> , 2022, 32, 629-647.	2.4	15
24	Structural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists. <i>Molecular Pharmacology</i> , 2015, 88, 238-244.	1.0	14
25	Ellagitannin Chemistry. Studies on the Stability and Reactivity of 2,4-HHDP-Containing Glucopyranose Systems. <i>Journal of Organic Chemistry</i> , 2003, 68, 7433-7438.	1.7	13
26	Antagonism of Sigma-1 receptor blocks heavy alcohol drinking and associated hyperalgesia in male mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 1398-1407.	1.4	10
27	Peripheral Hybrid CB1R and iNOS Antagonist MRI-1867 Displays Anti-Fibrotic Efficacy in Bleomycin-Induced Skin Fibrosis. <i>Frontiers in Endocrinology</i> , 2021, 12, 744857.	1.5	10
28	Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective $\frac{1}{4}$ -antagonist activity. <i>European Journal of Medicinal Chemistry</i> , 2012, 50, 44-54.	2.6	9
29	Recent progress in the discovery of ghrelin<i>O</i>-acyltransferase (GOAT) inhibitors. <i>RSC Medicinal Chemistry</i> , 2020, 11, 1136-1144.	1.7	8
30	Probes for Narcotic Receptor Mediated Phenomena. 38. An Expeditious Synthesis of rac-cis-4a-Ethyl-2-methyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ol and rac-cis-2-Methyl-4a-phenethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ol. <i>Heterocycles</i> , 2009, 79, 1061.	0.4	6
31	Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB1R) Receptor with Reduced Lipophilicity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2374-2387.	2.9	6
32	Probes for narcotic receptor mediated phenomena. 40. N-Substituted cis-4a-ethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-8-ols. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 91-99.	1.4	5
33	Synthesis of ¹³ C ₆ -labeled, dual-target inhibitor of cannabinoid-1 receptor (CB ₁ R) and inducible nitric oxide synthase (iNOS). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 773-779.	0.5	5
34	Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia. <i>Molecules</i> , 2021, 26, 5089.	1.7	4
35	Probes for narcotic receptor mediated phenomena. 47.1 Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 3298-3309.	1.4	2
36	Synthesis of ¹³ C ₂ -(4-chlorophenyl)-N-(4-chlorophenyl)-4,5-dihydro-1 <i>H</i> -octadecaterated JD5037. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 460-465.		

#	ARTICLE	IF	CITATIONS
37	Probes for narcotic receptor mediated phenomena 49. N-substituted rac-cis-4a-arylalkyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 531-539.	2.6	1
38	Characterization of a differential reinforcement of low rates of responding task in non-deprived male and female rats: Role of Sigma-1 receptors. <i>Neuropharmacology</i> , 2021, 200, 108786.	2.0	0